23andMe Files Chapter 11 as CEO Resigns \ Newslooks \ Washington DC \ Mary Sidiqi \ Evening Edition \ Genetic testing company 23andMe has filed for Chapter 11 bankruptcy protection. Co-founder and CEO Anne Wojcicki has stepped down amid financial turmoil and privacy concerns. The company plans to sell most assets through a court-approved reorganization plan.
23andMe Bankruptcy Quick Looks
- 23andMe files for Chapter 11 bankruptcy protection.
- Co-founder and CEO Anne Wojcicki resigns but stays on the board.
- Company plans to sell most assets via court-supervised reorganization.
- Wojcicki intends to bid for 23andMe as an independent buyer.
- Financial troubles followed unsuccessful attempts to go private.
- The company has struggled to find profitability since going public in 2021.
- Privacy concerns heightened after a 2023 data breach affecting 7 million users.
- 23andMe reported debts of $214.7 million at the end of 2023.
- Assets are estimated at $277.4 million.
- Workforce cuts included 40% layoffs and closure of its therapeutics division.
- Shares plunged to under $1 following bankruptcy filing.
- The company secured $35 million in bankruptcy financing from JMB Capital Partners.
- 23andMe plans to exit leases in San Francisco and Sunnyvale to reduce costs.
- California’s attorney general urged consumers to consider deleting their genetic data.
- Future ownership remains uncertain, raising fresh concerns about data privacy.
Deep Look
Once a pioneer in direct-to-consumer genetic testing, 23andMe has now entered one of the most challenging chapters in its history. On Sunday, the San Francisco-based company filed for Chapter 11 bankruptcy protection, signaling its intent to sell “substantially all of its assets” through a court-supervised process. The filing comes after years of financial struggles, a failed acquisition attempt, and increasing privacy concerns that have plagued the company.
Adding to the turmoil, co-founder and CEO Anne Wojcicki has stepped down from her leadership role, though she will remain on the board. Notably, she may still seek to buy back the company as it goes up for sale through the bankruptcy process. In a statement posted on social media, Wojcicki explained that stepping down as CEO put her “in the best position” as an independent bidder.
“There is no doubt that the challenges faced by 23andMe through an evolving business model have been real, but my belief in the company and its future is unwavering,” Wojcicki stated.
A Struggling Business Model and Growing Debt
23andMe was founded in 2006 with a vision to revolutionize genetic testing and personalized healthcare. Its saliva-based DNA testing kits became a household name, allowing millions of customers to explore their ancestry and genetic traits. The company later expanded into health research and pharmaceutical development, seeking to turn its vast database of genetic information into valuable medical insights.
Despite early success, 23andMe has struggled to maintain profitability. The company went public in 2021 through a SPAC (special purpose acquisition company) merger, but it has since faced mounting financial pressures. Shares have plummeted in value, and by the time of Sunday’s bankruptcy filing, the stock was trading at less than $1.
In September 2023, all of 23andMe’s independent board members resigned after failed negotiations to take the company private. Then in November, the company announced a massive restructuring plan that included laying off 40% of its workforce—more than 200 employees—and shutting down its therapeutics division.
By January 2024, the company’s board was openly exploring strategic alternatives, including a possible sale. With its latest Chapter 11 filing, 23andMe confirmed it had more than $214.7 million in total debt at the end of last year, compared to $277.4 million in assets.
In an effort to keep the business afloat during the bankruptcy process, 23andMe secured $35 million in debtor-in-possession financing from JMB Capital Partners. This loan is expected to cover operational expenses while the company seeks a buyer.
Legal and Privacy Concerns Mount
Beyond financial issues, 23andMe has also been grappling with growing concerns over data security and privacy. In 2023, a major data breach compromised the genetic and ancestral information of nearly 7 million customers. This exposed sensitive user data, raising alarms about how the company handles and protects genetic information.
Litigation related to the breach has contributed to the company’s mounting liabilities. In 2023, 23andMe agreed to a $30 million settlement in a class-action lawsuit accusing it of failing to adequately safeguard customer data. On Sunday, the company indicated that it hopes to use the bankruptcy proceedings to resolve remaining legal liabilities tied to the breach.
The potential sale of 23andMe also raises questions about the future of customer data. The company has assured users that bankruptcy will not change how it stores or protects genetic information. Board Chair Mark Jensen stated that data privacy will be a major consideration in any sale and that any potential buyer will need to comply with strict regulatory approvals.
However, some privacy advocates remain skeptical. California Attorney General Rob Bonta recently issued a public warning, urging 23andMe customers to consider deleting their genetic data. His office cited concerns about the company’s financial distress and the sensitive nature of its vast database of consumer DNA.
What’s Next for 23andMe?
23andMe’s future remains highly uncertain. The company’s bankruptcy filing is meant to facilitate a sale, but the identity of potential buyers remains unknown. Given the sensitive nature of genetic data, any acquisition will face intense regulatory scrutiny.
Wojcicki, despite stepping down, has positioned herself as a potential bidder in the upcoming sale. If she successfully reacquires the company, she could attempt to steer 23andMe back toward its original vision of genetic innovation. However, questions remain about whether the company can regain trust after years of financial losses, privacy breaches, and failed strategic pivots.
For existing customers, the most pressing question is what will happen to their genetic data. While 23andMe has pledged to maintain security, privacy advocates warn that changes in ownership could bring unforeseen risks. As the bankruptcy process unfolds, many will be watching closely to see whether one of the most well-known names in genetic testing can find a path forward—or if this marks the end of an era for consumer DNA services.
You must Register or Login to post a comment.